LONDON – Oxford University says the complex trial of its COVID-19 vaccine in Brazil will continue after reports of a participant’s death.
The university said it could only comment on express incidents, but an independent review found no explanation as to why to be involved in protecting The Brazilian trial.
It asserts that an “independent review, in addition to the Brazilian regulator, that the trial continues”.
The Oxford vaccine is being developed in collaboration with the pharmaceutical company AstraZeneca.
Trials are underway in the United States and the United Kingdom, as well as in Brazil, to determine whether the prospective vaccine is safe and effective in humans.